| ¿µ¹® | solid tumor | ÇÑ±Û | °íÇüÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷·Î ²Ë Âù Á¾¾çÀ» ¸»ÇÔ. ¹éÇ÷º´ µîÀÇ Ç÷¾×¾Ï°ú °°ÀÌ ÇüŸ¦ ÃëÇÏÁö ¾Ê°í ¾×üÀÎ »óÅÂÀÇ ¾Ï°ú ´ëÁ¶µÇ´Â ¿ë¾î·Î¼ ´Ü´ÜÇÑ µ¢¾î¸®·Î ±¸¼ºµÈ ¾Ç¼ºÁ¾¾çÀÌ´Ù. ´ëºÎºÐÀÇ Á¾¾çÀÌ ÀÌ¿¡ ÇØ´çÇÑ´Ù. ƯÈ÷ Ç¥ÇÇÁ¶Á÷¿¡¼ ±â¿øÇÑ Á¾¾çÀ» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | ulcerating tumor | ÇÑ±Û | ±Ë¾ç¼º Á¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¾¾çÀÇ Ç¥¸é¿¡ ±Ë¾çÀÌ ¹ß»ýÇÏ´Â °Í. ´ë°³, ¸Å¿ì »¡¸® ÀÚ¶ó´Â Á¾¾ç¿¡¼ Ç÷·ù °ø±ÞÀÌ Á¾¾ç¼¼Æ÷ÀÇ ÀÚ¶ó´Â ¼Óµµ¸¦ °¨´çÇÏÁö ¸øÇØ Á¾¾çÁ߽ɺΠÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁ® ±Ë¾çÀ» Çü¼ºÇÏ´Â °æ¿ì°¡ ¸¹´Ù. À°¾ÈÀ¸·Î º¸¸é »¡°²°í, ¿À̳ª¸ç, ÁöÀúºÐÇØ º¸ÀδÙ. |
||
| ¿µ¹® | brain tumor | ÇÑ±Û | ³úÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ³úÁ¾¾çÀ̶õ ³ú¿Í ³úÁ¶Á÷¿¡¼ »ý±ä Á¾¾çÀ» ÁöĪÇÏ´Â ¸»ÀÌ´Ù. ±×·¯³ª ´ë°³ ³ÐÀº Àǹ̷Π»ç¿ëÇÒ °æ¿ì¿¡´Â ¸Ó¸®»À¼ÓÀÇ °ø°£ÀÎ µÎ°³°¼Ó¿¡ »ý±â´Â ¸ðµç Á¾¾çÀ» À̸£´Â ¸»·Î »ç¿ëµÈ´Ù. ³úÁ¾¾çÀº ÇÑÁ¤µÈ °ø°£ÀÎ µÎ°³°¿¡¼ ¹ß»ýÇϹǷΠÁ¾¾çÀÌ ±×´ÙÁö Å©Áö ¾Ê¾Æµµ Á¤»óÀûÀÎ Á¶Á÷À» ¾Ð¹ÚÇÏ°Ô µÇ°í, µÎ°³°³»ÀÇ ¾Ð·ÂÀ» ³ôÀδÙ. ÀÌ·± Ư¡¿¡ ÀÇÇØ¼ ³úÁ¾¾çÀÇ Áõ»óÀº ´Ù¸¥ Á¾¾ç°ú ´Þ¸®, Á¾¾ç ±× ÀÚüÀÇ Áõ»óº¸´Ùµµ µÎ°³³»¾Ð»ó½Â°ú Á¤»óÁ¶Á÷ÀÇ ¾Ð¹Ú¿¡ ÀÇÇÑ Áõ»óÀÌ ¸¹´Ù. µÎ°³³»¾Ð(³ú¾Ð)ÀÇ »ó½Â¿¡ ÀÇÇÑ Áõ»óÀ¸·Î´Â µÎÅë, ±¸ÅäµîÀÌ ÀÖÀ¸¸ç, Áö¼ÓÀûÀÎ ³ú¾Ð»ó½Â¿¡ ÀÇÇØ¼ À¯µÎºÎÁ¾(papilledema)ÀÌ °üÂûµÇ±âµµ ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀÎ ³úÁ¶Á÷ÀÇ ¾Ð¹Ú°ú Á¾¾çÀÌ »ý±ä ºÎÀ§ÀÇ ±â´ÉÀÇ °áÇÕ¿¡ ³úÀÇ ±× ºÎºÐ¿¡ ÇØ´çÇÏ´Â ±â´ÉÀÇ »ó½ÇÀ» º¸°ÔµÈ´Ù. |
||
| ¿µ¹® | epithelial tumor | ÇÑ±Û | »óÇǼºÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¤»ó »ç¶÷ÀÇ Á¶Á÷Àº üǥ¸éÀ» µ¤´Â ¿ªÇÒÀ» ÇÏ´Â Á¶Á÷°ú, ÁÖ·Î ¹ß»ý±âÀÇ Á߹迱¿¡¼ ºÐÈÇÑ °£¿±Á¶Á÷¿¡¼ À¯·¡ÇÏ´Â °áÇÕÁ¶Á÷, »À, ¿¬°ñ, Áö¹æ, ±ÙÀ°, Ç÷°ü µîÀÇ Á¶Á÷ÀÇ µÎ °èÅëÀ¸·Î ³ª´ ¼ö ÀÖ´Ù. ÀüÀÚ¸¦ »óÇǼº Á¶Á÷, ÈÄÀÚ¸¦ ºñ»óÇǼº Á¶Á÷À̶ó ÇÏ¸ç ±× °¢°¢À» ±¸¼ºÇÏ´Â ¼¼Æ÷¸¦ »óÇǼº ¼¼Æ÷, ºñ»óÇǼ¼Æ÷¶ó ÃÑĪÇÑ´Ù. »óÇǼº ¼¼Æ÷¿¡¼ ±â¿øÇÏ´Â Á¾¾çÀÌ »óÇǼº Á¾¾çÀ̸ç, ±ÙóÀÇ Á¶Á÷À¸·Î ħÅõ³ª Ç÷·ù, ¸²ÇÁÀÇ Á¶Á÷À» Ÿ°í ¿ø°Å¸®ÀÇ Àå±â·Î À̵¿ÇÏÁö ¾Ê´Â ¾ç¼ºÁ¾¾ç¿¡´Â ¼±Á¾, À¯µÎÁ¾ µîÀÌ ÀÖ°í ¾ç¼º°ú ¹Ý´ë·Î ±ÙóÀÇ Á¶Á÷À¸·Î ħÅõ, ¿ø°ÝÀå±â·Î ÀüÀÌÇÏ´Â ¾Ç¼ºÁ¾¾çÀ» ¸ðµÎ ÅëĪÇÏ¿© ¾ÏÁ¾(carcinoma)À̶ó°í ÇÑ´Ù. |
||
| ¿µ¹® | medullary tumor | ÇÑ±Û | ¼öÁú¼º Á¾¾ç |
|---|---|---|---|
| ¼³¸í | ¾ÏÀÇ º´¸®ÇÐÀûÀÎ ºÐ·ùÁß Çϳª. ¿©·¯ ±â°üÀÇ ¾Ï¿¡¼ ³ªÅ¸³ª´Âµ¥ ÁÖ·Î °©»ó»ù¾ÏÀ̳ª À¯¹æ¾Ï¿¡¼ º¸ÀδÙ. |
||
| MMM | see 3-M [syndrome]; microsome-mediated mutagenesis; myelofibrosis with myeloid metaplasia; myeloscle... |
|---|---|
| GCT | general care and treatment; germ-cell tumor; giant cell thyroiditis; giant cell tumor |
| AFP | Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| CT | calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ... |
| MC | mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med... |
| EMH | Extramedullary haematopoiesis |
|---|---|
| MNDA | myeloid cell nuclear differentiation antigen |
| AML | Acute Myeloid Leukaemia |
| AMM | Agnogenic myeloid metaplasia |
| CML | Chronic Myeloid Leukaemia |
| haematopoiesis, extramedullary | The formation and development of blood cells outside the bone marrow, as in the spleen, liver, or lymph nodes. (12 Dec 1998) |
|---|---|
| intradural-extramedullary mass | <radiology> Meniscus sign, neurofibroma / schwannoma, meningioma, drop metastasis, lipoma, dermoid, angioma, ependymoma of filum terminale (really intramedullary) (12 Dec 1998) |
| tumor | 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant. 2. Swelling, one of the cardinal signs of inflammations, morbid enlargement. Origin: L. Tumere = to swell (12 May 1997) |
| tumor marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| tumor necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
| extramedullary | Outside of, or unrelated to, any medulla, especially the medulla oblongata. (05 Mar 2000) |
| myeloid cell | <haematology, pathology> One of the two classes of marrow derived blood cells, includes megakaryocytes, erythrocyte precursors, mononuclear phagocytes and all the polymorphonuclear granulocytes. That all these are ultimately derived from one stem cell lineage is shown by the occurrence of the Philadelphia chromosome in these, but not lymphoid, cells. most authors tend, however, to restrict the term myeloid to mononuclear phagocytes and granulocytes and commonly distinguish a separate erythroid lineage. (12 May 1997) |
| acute myeloid leukaemia | <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children. Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains. Treatment includes chemotherapy and/or bone marrow transplant. This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy. Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia. Acronym: AML Incidence: 2,000 new cases per year in the UK. Origin: Gr. Haima = blood (07 Apr 1998) |
| agnogenic myeloid metaplasia | A progressive disease of the bone marrow where neoplastic bone marrow stem cells lodge and grow in multiple sites outside the bone marrow. Typically, there is enlargement of the spleen and a gradual replacement of the bone marrow elements by fibrosis (scarring), progressive anaemia and variable changes in the number of white blood cells and platelets. Diagnosis is by bone marrow biopsy. There is no definitive treatment for this disorder that has been shown to affect life span favorably. Origin: Gr. Plassein = to form (27 Sep 1997) |
| chronic myeloid leukaemia | <haematology> A leukaemia which is initially slowly-progressing. There are approximately 650 new cases each year in the UK. It is characterised by the presence of large numbers of abnormal mature granulocytes, circulating in the blood. Synonym: chronic granulocytic leukaemia. Acronym: CML Origin: Gr. Haima = blood (12 Jan 1998) |
| myeloid | Collective term for the nonlymphocyte groups of white blood cells. It includes cells from the granulocyte, monocyte and platelet lineages. (13 Nov 1997) |
| myeloid metaplasia | A progressive disease of the bone marrow where neoplastic bone marrow stem cells lodge and grow in multiple sites outside the bone marrow. Typically, there is enlargement of the spleen and a gradual replacement of the bone marrow elements by fibrosis (scarring), progressive anaemia and variable changes in the number of white blood cells and platelets. Diagnosis is by bone marrow biopsy. There is no definitive treatment for this disorder that has been shown to affect life span favorably. Origin: Gr. Plassein = to form (27 Sep 1997) |
| myeloid sarcoma | <tumour> A malignant tumour of immature myeloid cells, frequently subperiosteal, associated with or preceding granulocytic leukaemia. See: chloroma. Synonym: myeloid sarcoma. (05 Mar 2000) |
| myeloid series | The granulocytic and the erythrocytic series. (05 Mar 2000) |
| myeloid tissue | Bone marrow consisting of the developmental and adult stages of erythrocytes, granulocytes, and megakaryocytes in a stroma of reticular cells and fibres, with sinusoidal vascular channels. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|